SCHEMBL5537574

SCHEMBL5537574

c1ccc(C2CN(c3ccccc3)CC(c3ccccc3)[N]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.47
ALPL P05186 2/20 0.46
MAPK1 P28482 2/20 0.46
ALPI P09923 1/20 0.46
ADRA2B P18089 1/20 0.46
DRD1 P21728 1/20 0.46
KCNH2 Q12809 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
TSHR P16473 1/20 0.46
ALOX12 P18054 1/20 0.46
NFKB1 P19838 1/20 0.46
LMNA P02545 3/20 0.45
ALDH1A1 P00352 1/20 0.45
PMP22 Q01453 1/20 0.45
BLM P54132 1/20 0.45
NOTUM Q6P988 1/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094438 0.77 MAPK1 (0.45) BPTFALPLMAPK1ALPIADRA2B
SCHEMBL6311085 0.72 NOS1 (0.45) KCNH2CYP1A2CYP2D6TSHRLMNA
SCHEMBL2280578 0.69 BPTF (0.54) BPTFMAPK1CYP1A2CYP2D6TSHR
SCHEMBL3121777 0.69 BPTF (0.54) BPTFMAPK1KCNH2TSHRNFKB1
SCHEMBL6621014 0.69 BPTF (0.54) BPTFMAPK1CYP1A2CYP2D6TSHR
SCHEMBL6403525 0.69 BPTF (0.54) BPTFMAPK1KCNH2NFKB1LMNA
SCHEMBL2330436 0.69 BPTF (0.54) BPTFMAPK1KCNH2TSHRNFKB1
SCHEMBL6990841 0.69 BPTF (0.54) BPTFMAPK1KCNH2CYP2D6NFKB1
SCHEMBL19139371 0.69 BPTF (0.54) BPTFMAPK1NFKB1LMNAALDH1A1
SCHEMBL17027050 0.68 NOTUM (0.72) BPTFTSHRALDH1A1NOTUMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 BPTF 1084/4885ALPL 3589/4885MAPK1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.